araag2/HINT huggingface dataset:
Clinical trial NCT00071487 (phase 2, status: completed)
Conditions: lupus erythematosus, systemic
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: placebo, belimumab 1 mg/kg, belimumab 4 mg/kg, belimumab 10 mg/kg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Primary Inclusion Criteria

          -  Clinical diagnosis of SLE

          -  "Active" SLE disease

          -  On a stable SLE treatment regimen

          -  History of measurable autoantibodies

        Primary Exclusion Criteria

          -  Received a non-FDA approved investigational agent within last 28 days

          -  Cyclosporin, intravenous immunoglobulin (IVIG) or plasmapheresis within last 90 days

          -  Active lupus nephritis requiring hemodialysis, cyclophosphamide (Cytoxan™), or
             high-dose prednisone (> 100 mg/day) within last 90 days

          -  Active central nervous system (CNS) lupus requiring therapeutic intervention within
             last 60 days

          -  History of renal transplant

          -  History of chronic infection that has been active within last 6 months, herpes zoster
             within last 90 days or any infection requiring hospitalization or intravenous
             medication within last 60 days

          -  History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency

          -  Human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C
Clinical trial NCT00503594 (phase 2, status: unknown status)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: methotrexate and temozolomide, methotrexate , procarbazine ,vincristine ,cytarabine
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  primary central nervous system lymphoma histologically confirmed by brain biopsy, CSF
             cytology or vitrectomy

          -  KPS 40 or higher

          -  Absence of systemic disease as evaluated by chest-abdomen-pelvis CT scan

          -  Leucocytes>3.500/mm3, platelets>130.000/mm3, Bilirubin < 2 mg, transaminases < 2.5 N),
             creatinine < 150 μM/l, creatinine clearance > 40 ml/min

          -  Age ≥ 60 years

          -  Negative HIV test

          -  Signature of informed consent

        Exclusion Criteria:

          -  previous cranial radiotherapy

          -  prior chemotherapy for primary central nervous system lymphoma

          -  presence of another cancer (excepting basal cell carcinoma of the skin and cervical
             carcinoma in situ )

          -  systemic lymphoma (outside the CNS)

          -  Isolated ocular lymphoma

          -  Immunosuppressed patients (HIV , use of immunosuppressors)

          -  Other uncontrolled or progressive disease compromising shot-term survival

          -  Severe renal or hepatic disease

          -  Patients not legally covered by the French Social Security

          -  Inability to swallow the medication
Clinical trial NCT00322842 (phase 2, status: completed)
Conditions: lymphoma, non-hodgkin, multiple myeloma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00
Drugs: g-csf plus plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for
             autologous transplantation

          -  No more than 3 prior regimens of chemotherapy

          -  More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute
             toxic effects of prior chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  White blood cell (WBC) count >3.0*10^9/L

          -  Absolute polymorphonuclear cells (PMN) count >1.5*10^9/L

          -  Platelet (PLT) count >100*10^9/L

          -  Serum creatinine <=2.2 mg/dL

          -  Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase
             (SGPT) and total bilirubin <2 x upper limit of normal (ULN)

          -  Left ventricle ejection fraction >45% by normal echocardiogram or multiple-gated
             acquisition (MUGA) scan

          -  Negative for human immunodeficiency virus (HIV)

          -  Women of child bearing potential who agreed to use an approved form of contraception.

        Exclusion Criteria:

          -  Patients who have failed previous collections

          -  Brain metastases or carcinomatous meningitis

          -  History of ventricular arrhythmias

          -  History of paresthesias

          -  A co-morbid condition which, in the view of the investigator, renders the patient at
             high risk for treatment complications

          -  A residual acute medical condition resulting from prior chemotherapy

          -  Acute infection

          -  Fever (temp >38°C/100.4°F)

          -  Patients whose actual body weight exceeds 150% of their ideal body weight

          -  Patients who previously received experimental therapy within 4 weeks of enrolling in
             this study or who are currently enrolled in another experimental study during the
             mobilization period

          -  Positive pregnancy test in female patients

          -  Lactating females

          -  Patients of child-bearing potential unwilling to implement adequate birth control.

          -  Patients who have deterioration of their clinical status or laboratory parameters
             between the time of enrolment and transplant (such that they no longer meet entry
             criteria) may be removed from study at the discretion of the treating physician,
             principal investigator, or sponsor.
Clinical trial NCT00263276 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin, dapagliflozin, placebo, metformin
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with Type 2 diabetes mellitus with inadequate glycemic control on diet and
             exercise. HbA1c >= 7% and <=10%.

          -  Patient either has not been previously treated with antihyperglycemic medication or
             has been treated for <30 days since diagnosis and has received less than 3 consecutive
             doses or 7 non-consecutive doses in the last 30 days.

          -  C-peptide > 1.0 ng/ml

          -  Body Mass Index <= 40 kg/m2

          -  Serum creatinine < 1.5 mg/dL for men or < 1.4 mg/dL for women.

          -  No overt proteinuria (microalbumin/creatinine ratio must be <300 mg/g

        Exclusion Criteria:

          -  Unstable renal disease

          -  Patients with significant liver disease including chronic active hepatitis

          -  Within the last 6 months has had any of the following cardiovascular event: myocardial
             infarction, unstable angina, unstable CHF,NYHA Class III or IV CHF, TIA, unstable
             arrhythmia or cardiac revascularization surgery.

          -  Subjects with clinically significant anemia
Clinical trial NCT00634413 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: theophylline - adc4022, placebo, budesonide
SMILES: CN1C2=C(NC=N2)C(=O)N(C)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of COPD that has been symptomatic for at least 2 years

          -  The subject has moderate to severe COPD, as defined by the American Thoracic Society
             and the European Respiratory Society

          -  The subject can produce an adequate sputum specimen after induction

          -  The subject has a history of ≥ 10-pack years of cigarette smoking

          -  The subject has either a ≤15% increase or ≤200 ml increase in FEV1 from pre-dose
             following a fixed dose of bronchodilator therapy

          -  The subject is able to provide written, informed consent to participate

        Exclusion Criteria:

          -  The subject has experienced a respiratory tract infection and/or an exacerbation of
             COPD within 30 days

          -  The subject uses systemic corticosteroids (oral or parenteral)

          -  The subject has received long term oxygen therapy within 30 days

          -  The subject has a previous history or diagnosis of asthma

          -  The subject has a chest x-ray within the past 12 months which is diagnostic of an
             active or clinically significant disease other than COPD

          -  The subject has a history or presence of active tuberculosis, cystic fibrosis,
             bronchiectasis, lung cancer or sarcoidosis or any other clinically important lung
             diseases

          -  The subject has had radiation or chemotherapy within the previous 12 months

          -  The subject has a history of anaphylaxis associated with medicinal products

          -  The subject is pregnant, intends to become pregnant, or is breast feeding

          -  The subject's alcohol intake is excessive.

          -  The subject participated in another study (for a marketed drug) within 3 months before
             the start of this study or (for an investigational drug) within 4 months before the
             start of this study.

        Other inclusion/exclusion criteria may also apply
Clinical trial NCT00605722 (phase 2, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: bevacizumab (avastin), erlotinib (tarceva)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, ≥ 18 years of age;

          -  advanced or metastatic liver cancer;

          -  ≥ 1 measurable lesion, not previously treated with local therapy within 4 weeks of
             enrollment.

        Exclusion Criteria:

          -  prior or concomitant systemic anti-cancer treatment for advanced disease;

          -  patients at high risk of variceal bleeding;

          -  clinically significant cardiovascular disease;

          -  major surgery, open biopsy, or significant traumatic injury within 4 weeks of study
             start.
Clinical trial NCT01263470 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin, alogliptin, alogliptin, alogliptin, voglibose, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after
             the start of screening(Week -4).

          -  A HbA1c differences within 10.0%* (*rounded off to the first decimal point) at the
             start of screening (Week -8) and 4 weeks after the start of screening (Week -4) from
             the HbA1c value at the start of screening.

          -  Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4
             weeks or longer before the start of screening (Week -8).

        Exclusion Criteria:

          -  Received any antidiabetic drug within the last 4 weeks before the start of screening
             (Week -8) or during screening.
Clinical trial NCT00598078 (phase 2, status: completed)
Conditions: essential tremor
ICD codes: G25.0
Drugs: sodium oxybate, sodium oxybate
SMILES: [Na+].OCCCC([O-])=O, [Na+].OCCCC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of moderate or severe classic essential tremor (bilateral, largely symmetric
             postural or kinetic tremor involving hands and forearms.

          -  Willingness to abstain from ethanol and caffeine intake for at least 48 hours prior to
             Days 1 and 4 and on inpatient days

        Exclusion Criteria:

          -  Subjects with a clinically significant unstable medical abnormality, chronic disease
             or history or presence of significant hepatic, renal, endocrine, cardiovascular,
             gastrointestinal, pulmonary, psychiatric, or metabolic disease or any other
             abnormality

          -  Subjects who are on sodium-restricted diets

          -  Subjects with a known history of sleep apnea
Clinical trial NCT01052103 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ly2140023, placebo, standard of care
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia

          -  Patients must have been receiving monotherapy treatment for at least 3 months prior to
             study entry with one of 4 atypical antipsychotic medications (aripiprazole,
             olanzapine, risperidone, quetiapine)

          -  Disease symptoms must meet a certain range as assessed by the clinician

          -  Patients must have evidence of prominent negative symptoms of schizophrenia (i.e.
             blunted affect, emotional withdrawal, or motor retardation)

          -  Patients must be considered reliable, have a level of understanding sufficient to
             perform all tests and examinations required by the protocol, and be willing to perform
             all study procedures

          -  Patients must be able to understand the nature of the study and have given their
             informed consent

        Exclusion Criteria:

          -  Patients who are actively suicidal

          -  Patients who are pregnant or nursing

          -  Patients who have had electroconvulsive therapy (ECT) within 3 months of screening or
             who will have ECT at any time during the study

          -  Patients with uncorrected narrow-angle glaucoma, history of or current seizure
             disorder, uncontrolled diabetes, certain diseases of the liver, renal insufficiency,
             uncontrolled thyroid condition or other serious or unstable illnesses

          -  Patients with Parkinson's disease, psychosis related to dementia or related disorders

          -  Patients with known Human Immunodeficiency Virus positive (HIV+) status
Clinical trial NCT00454116 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: vandetanib, folfiri
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed colorectal cancer

          -  Have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen
             defined as:

          -  Progression on or following treatment for metastatic colorectal cancer

          -  Progression within 12 months of adjuvant chemotherapy for colorectal cancer

        Exclusion Criteria:

          -  Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR eg,
             erlotinib, gefitinib. Prior monoclonal antibodies are permitted, eg, cetuximab,
             bevacizumab.

          -  Previous adjuvant therapy with irinotecan within 12 months of randomization

          -  More than one prior course of chemotherapy for treatment of metastatic colorectal
             cancer.
Clinical trial NCT01015677 (phase 2, status: terminated)
Conditions: moderate to severe vasomotor symptoms in postmenopausal, women
ICD codes: N95.0, N95.2
Drugs: mk-6913, 17-β estradiol, placebo to mk-6913, placebo to 17-β estradiol, mk-6913 25 mg
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Woman with at least 50 moderate to very severe hot flash episodes per week

          -  Postmenopausal

          -  Between 45 and 60 years of age if naturally menopausal, or between 35 and 60 if she
             underwent a bilateral oophorectomy

          -  Not receiving hormone therapy

          -  Has had both a normal mammogram and a normal Pap test in the past 6 months

          -  Generally healthy

        Exclusion Criteria:

          -  A history of cancer, except for certain skin cancers

          -  Undiagnosed vaginal bleeding or any uterine endometrial disorder

          -  Currently uses tobacco products, or has used them in the last 6 months

          -  Has human immunodeficiency virus (HIV)
Clinical trial NCT01024036 (phase 2, status: completed)
Conditions: multicentric castleman's disease
ICD codes: D47.Z2
Drugs: siltuximab, placebo, best supportive care (bsc)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Measurable and symptomatic Multicentric Castleman's Disease

          -  Adequate organ function as assessed by laboratory values evaluated by the investigator
             to determine eligibility prior to treatment

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2

          -  Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone, and has remained
             stable or decreased over the 4 weeks before treatment

        Exclusion Criteria:

          -  Human Immunodeficiency Virus or Human Herpes Virus-8 positive

          -  Skin lesions as sole measurable manifestation of Multicentric Castleman's Disease

          -  Previous history of lymphoma

          -  Malignancies, except for adequately treated basal cell or squamous cell carcinoma of
             the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which
             the patient has been disease-free for 3 or more years

          -  Concurrent medical condition or disease that may interfere with study participation

          -  Prior exposure to Interleukin-6 or Interleukin-6 receptor targeted therapies
Clinical trial NCT00130195 (phase 2, status: completed)
Conditions: acute lymphoblastic leukemia
ICD codes: C91.01, C91.02, C91.00
Drugs: imatinib, cyclophosphamide, daunorubicin, vincristine, prednisolone, methotrexate, cytarabine, dexamethasone
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated BCR-ABL-positive ALL

          -  Age between 15 and 64 years

          -  Performance status between 0 and 3 (ECOG criteria)

          -  Adequate functioning of the liver (serum bilirubin level < 2.0 mg/dL), kidneys (serum
             creatinine level < 2.0 mg/dL), and heart (left ventricular ejection fraction greater
             than 50% and no severe abnormalities detected on electrocardiograms and
             echocardiographs)

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Uncontrolled active infection

          -  Another severe and/or life-threatening disease

          -  Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests

          -  Another primary malignancy which is clinically active and/or requires medical
             interventions

          -  Pregnant and/or lactating women

          -  Past history of renal failure
Clinical trial NCT01190462 (phase 2, status: unknown status)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: simvastatin
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of advanced or metastatic colorectal cancer

          -  Progressive disease in the past 3 months

          -  Failed prior oxaliplatin-, fluorouracil (5-FU)-, and irinotecan-containing regimens
             AND have the presence of a k-ras mutation within codon 12, 13, or 61

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  Adequate organ function

          -  No history of toxicity during statin use

          -  No other malignancy within the past 5 years

          -  No history of severe pulmonary disease

          -  No clinically relevant coronary artery disease

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior epidermal growth factor receptor (EGFR)-targeting agents

          -  No concurrent verapamil or amiodarone
Clinical trial NCT00004039 (phase 2, status: withdrawn)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    no patient accruals
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed high risk (stage III or IV) indolent or
        intermediate (stage II to IV) B-cell lymphoma Small cleaved cell lymphoma Waldenstrom's
        macroglobulinemia Follicular small cleaved cell or mixed cell Follicular large cell Diffuse
        Immunoblastic High risk is defined as: Increased LDH OR Increased beta-2-microglobulin OR B
        symptoms OR Bulky disease of greater than 7 cm in diameter OR Extranodal disease other than
        blood or bone marrow involvement OR Mantle zone histology At least 1 lymph node or visceral
        lesion at least 2 cm in diameter

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
        Other: No active infection or other medical condition this is lifethreatening Not pregnant
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: No prior therapy for lymphoma